Vetr Inc. announced Kite Pharma Inc (NASDAQ:KITE), boosting its stock price target to $63.91 today
- Updated: September 16, 2016
Yesterday Kite Pharma Inc (NASDAQ:KITE) traded 4.08% higher at $57.00. The company’s 50-day moving average is $58.64 and its 200-day average is $51.40. With the last stock close up 12.12% relative to the two hundred day moving average, compared to the Standard & Poor’s 500 Index which has fallen -0.01% over the same time period. 962,257 shares of the stock traded, up from ann average volume of 819,252.
Vetr Inc. upped the price target of Kite Pharma Inc (NASDAQ:KITE) to $64, indicating a possible upside of 0.12%,
On 9/07/2016, Vetr Inc. released a statement on Kite Pharma Inc(NASDAQ:KITE) bumped the target price from $0.00 to $63.91. At the time, this suggested an upside of 0.06%.
A total of 11 firms have released a report on the company. Six firms rate the stock a strong buy, seven firms rate the stock a buy, 0 analysts rate the company a hold, 0 rate the company to underperform, and finally 0 firmsrate the company as sell with a one year target of $74.18
With a total market value of $0.0, Kite Pharma Inc has a 52 week low of $38.41 and a one-year high of $89.84 with a P/E ratio of 0.
General Company Details For Kite Pharma Inc (NASDAQ:KITE)
Kite Pharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products to eradicate cancer cells. The Company offers engineered autologous cell therapy (eACT), which is an approach to the treatment of cancer. It is conducting over four pivotal studies of its lead product candidate, KTE-C19, a CAR-based therapy. It is conducting a Phase II clinical trial (ZUMA-1) of KTE-C19 in patients with refractory diffuse large B cell lymphoma (DLBCL), including primary mediastinal B cell lymphoma (PMBCL) and transformed follicular lymphoma (TFL). It is also conducting a Phase II clinical trial (ZUMA-2) of KTE-C19 in patients with relapsed/refractory mantle cell lymphoma (MCL), a Phase I-II clinical trial (ZUMA-3) of KTE-C19 in adult patients with relapsed/refractory acute lymphoblastic leukemia (ALL), and and a Phase I-II clinical trial (ZUMA-4) of KTE-C19 in pediatric patients with relapsed/refractory ALL.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.